Intracellular Mutual Promotion of Redox Homeostasis Regulation and Iron Metabolism Disruption for Enduring Chemodynamic Therapy

Yang Liu,Shaojie Zhai,Xingwu Jiang,Yanyan Liu,Kun Wang,Chaochao Wang,Meng Zhang,Xuanyong Liu,Wenbo Bu
DOI: https://doi.org/10.1002/adfm.202010390
IF: 19
2021-02-19
Advanced Functional Materials
Abstract:Abstract Intracellular redox homeostasis and the iron metabolism system in tumor cells are closely associated with the limited efficacy of chemodynamic therapy (CDT). Despite extensive attempts, maintaining high levels of intracellular catalysts (free iron) and reactants (H 2 O 2 ) while decreasing the content of reactive oxygen species (ROS) scavengers (especially glutathione (GSH)) for enduring CDT still remains great challenges. Herein, SS bond‐rich dendritic mesoporous organic silica nanoparticles (DMON) are utilized as GSH‐depleting agents. After co‐loading Fe 0 and a catalase inhibitor (3‐amino‐1,2,4‐triazole (AT)), a novel biodegradable nanocarrier is constructed as DMON@Fe 0 /AT. In the mildly acidic tumor microenvironment, on‐demand ferrous ions and AT are intelligently released. AT suppresses the activity of catalase for H 2 O 2 hoarding, and the exposed DMON weakens ROS scavenging systems by persistently depleting intracellular GSH. The highly efficient •OH production by DMON@Fe 0 /AT can effectively attack mitochondria and downregulate the expression of ferroportin 1, which can disrupt the cellular iron metabolism system, leading to the desired retention of iron in the cytoplasm. More importantly, DMON@Fe 0 /AT exhibits a much more efficient CDT killing effect on 4T1 tumor cells than plain Fe 0 nanoparticles, benefiting from their synergistic redox regulation and iron metabolism disruption. Overall, the as‐prepared intelligent, degradable DMON@Fe 0 /AT provides an innovative strategy for enduring CDT.
materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
What problem does this paper attempt to address?
The paper primarily focuses on addressing two major challenges encountered in Chemodynamic Therapy (CDT) for tumor treatment: intracellular iron metabolism and redox homeostasis. Specifically, it is necessary to maintain high levels of free iron and hydrogen peroxide (H2O2) within tumor cells to promote effective CDT, while reducing the content of antioxidants such as glutathione (GSH) to enhance therapeutic effects. However, intracellular iron can be transported, utilized, or excreted through various pathways, making it difficult to maintain high concentrations of free iron in the cytoplasm; simultaneously, tumor cells possess a powerful antioxidant system capable of rapidly eliminating excess reactive oxygen species (ROS), thereby reducing the efficiency of CDT. To address the aforementioned issues, the research team designed a novel type of nanocarrier—disulfide-bond-rich mesoporous organosilica nanoparticles (DMON), which are loaded with zero-valent iron (Fe^0) and the hydrogen peroxide enzyme inhibitor 3-amino-1,2,4-triazole (AT). This DMON@Fe^0/AT nanocarrier can intelligently release Fe^2+ ions and AT under the slightly acidic conditions of the tumor microenvironment. AT can inhibit the activity of hydrogen peroxide enzymes, allowing H2O2 to accumulate, while DMON continuously consumes GSH to weaken the cell's antioxidant system, thereby enhancing the therapeutic effect of CDT. Additionally, DMON@Fe^0/AT can generate highly efficient hydroxyl radicals (•OH), effectively attacking mitochondria and downregulating the expression of iron transport protein 1 (FPN1), disrupting the intracellular iron metabolism system, and promoting the stable retention of iron in the cytoplasm, further enhancing the effect of CDT. In summary, this intelligent and degradable DMON@Fe^0/AT nanocarrier provides an innovative strategy for sustained chemodynamic therapy by synergistically regulating intracellular redox balance and interfering with iron metabolism. It demonstrates high-efficiency cytotoxicity against 4T1 tumor cells and has been validated in a mouse model for its excellent antitumor effects and biosafety.